Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
2006-10-10
2006-10-10
O'Hara, Eileen B. (Department: 1647)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
C530S300000, C514S002600
Reexamination Certificate
active
07119165
ABSTRACT:
Disclosed are NgR proteins and biologically active Nogo (ligand) protein fragments. Also disclosed are compositions and methods for modulating the expression or activity of the Nogo and NgR protein. Also disclosed are peptides which block Nogo-mediated inhibition of axonal extension. The compositions and methods of the invention are useful in the treatment of cranial or cerebral trauma, spinal cord injury, stroke or a demyelinating disease.
REFERENCES:
patent: 5250414 (1993-10-01), Schwab et al.
patent: 5684133 (1997-11-01), Schwab et al.
patent: 5858708 (1999-01-01), Bandman et al.
patent: 6025333 (2000-02-01), Schwab et al.
patent: 6475753 (2002-11-01), Ruben et al.
patent: 6627741 (2003-09-01), Ruben et al.
patent: 6774216 (2004-08-01), Ruben et al.
patent: 2002/0012965 (2002-01-01), Strittmatter
patent: 2002/0055139 (2002-05-01), Holtzman et al.
patent: 2003/0124704 (2003-07-01), Strittmatter et al.
patent: 2005/0221420 (2005-10-01), Barske et al.
patent: 2005/0271655 (2005-12-01), Lee et al.
patent: WO 98/06841 (1998-02-01), None
patent: WO 99/46281 (1999-09-01), None
patent: WO 99/66041 (1999-12-01), None
patent: WO 00/05364 (2000-02-01), None
patent: WO 00/31235 (2000-06-01), None
patent: WO 00/32221 (2000-06-01), None
patent: WO 00/37638 (2000-06-01), None
patent: WO 00/53756 (2000-09-01), None
patent: WO 00/53758 (2000-09-01), None
patent: WO 00/58473 (2000-10-01), None
patent: WO 00/70050 (2000-11-01), None
patent: WO 00/73452 (2000-12-01), None
patent: WO 01/09162 (2001-02-01), None
patent: WO 01/51520 (2001-07-01), None
patent: WO 02/29059 (2002-04-01), None
patent: WO 03/031462 (2003-04-01), None
patent: WO 04/014311 (2004-02-01), None
patent: WO 05/016955 (2005-02-01), None
Fournier, et al, 2001, Nature, 419: 341-346; Barton, et al, 2003, 22(13): 3291-3302.
Barton, et al, 2003, 22(13): 3291-3302.
Huizinga, et al, 2002, Science, 297: 1176-1179.
Hall, A., 1998, Science, 278, 509-514.
C. E. Bandtlow, et al., “NI-35/250/Nogo-A: A Neurite Growth Inhibitor Restricting Structural Plasticity and Regeneration of Nerve Fibers in the Adult Vertebrate CNS,”Glia, 29(2), pp. 175-181 (2000).
M.S. Chen, et al., “Nogo-A is a Myelin-Associated Neurite Outgrowth Inhibitor and an Antigen for monoclonal Antibody IN-1,”Nature, 403(6768), pp. 434-439 (2000).
A.E. Fournier, et al., “Identification of a Receptor Mediating Nogo-66 Inhibition of Axonal Regeneration,”Nature, 409(6818), pp. 341-346 (2001).
T. GrandPre, et al., “Identification of the Nogo Inhibitor of Axon Regeneration as a Reticulon Protein,”Nature, 403(6768), pp. 439-444 (2000).
P. Hu, et al., “Homo SapiensChromosome 22q11 PAC Clone p215k21 Distal to DGCR Region,”EMBL Database Entry AC006549, Accession No. AC006549 (1999).
A.B. Huber, et al., “Nogo-A, a Potent Inhibitor of Neurite Outgrowth and Regeneration,”Biol. Chem., 381(5-6), pp. 407-419 (2000).
D. Merkler, et al., “Locomotor Recovery in Spinal Cord-Injured Rats Treated with an Antibody Neutralizing the Myelin-Associated Neurite Growth Inhibitor Nogo-A,”J. Neurosci., 21(10), pp. 3665-3673 (2001).
M. Oudega, et al., “Neutralizing Antibodies Against Neurite Growth Inhibitor NI-35/250 Do Not Promote Regeneration of Sensory Axons in the Adult Rat Spinal Cord,”Neuroscience, 100(4), pp. 873-883 (2000).
R. Prinjha, et al., “Inhibitor of Neurite Outgrowth in Humans,”Nature, 430(6768), pp. 383-384 (2000).
O. Raineteau, et al., “Sprouting and Regeneration After Pyramidotomy and Blockade of the Myelin-Associated Neurite Growth Inhibitors N1 35/250 in Adult Rats,”Eur. J. Neurosci., 11(4), pp. 1486-1490 (1999).
O. Raineteau, et al., “Functional Switch Between Motor Tracts in the Presence of the mAB IN-1 in the Adult Rat,”Proc. Natl. Acad. Sci. U.S.A., 98(12), pp. 6929-6934 (2001).
A.A. Spillmann, et al., “Identification and Characterization of a Bovine Neurite Growth Inhibitor (bNI-22),”J. Biol. Chem., 273(30), pp. 19283-19293 (1998).
M. Tatagiba, et al., “Regeneration of Injured Axons in the Adult Mammalian Central Nervous System,”Neurosurgery, 40(3), pp. 541-547 (1997).
M. Thallmair, et al., “Neurite Growth Inhibitors Restrict Plasticity and Functional Recovery Following Corticospinal Tract Lesions,”Nat. Neurosci., 1(2), pp. 124-131 (1998).
W.J. Z′Graggen, et al., “Functional Recovery and Enhanced Corticofugal Plasticity After Unilateral Pyramidal Tract Lesion and Blockade of Myelin-Associated Neurite Growth Inhibitors in Adult Rats,”J. Neurosci., 18(12), pp. 4744-4757 (1998).
International Search Report for International Application No. PCT/US05/35719, ISA/US, Alexandria, VA, mailed Apr. 13, 2006.
Supplementary European Search Report for European Patent Application No. EP 02 80 0939, European Patent Office, mailed on Jun. 28, 2005.
Fournier, A.E., et al., “Characterization of the neuronal receptor mediating Nogo-66 inhibition of axonal regeneration,”J. Neurochem. 78 (Suppl. 1): 105, Blackwell Publishing, Abstract No. S08-01 (Sep. 2001).
Fournier, A.E., et al., “Nogo Receptor Domain Analysis,”Society for Neuroscience Abstracts27:670, Society for Neuroscience, Abstract No. 258.3, presented at theSociety for Neuroscience's 31st Annual Meeting, San Diego, CA (Nov. 12, 2001).
GrandPre, T.J., et al., “Functional Analysis of Nogo-66 and Nogo Receptor Domains,”Society for Neuroscience Abstracts27:670, Society for Neuroscience, Abstract No. 258.4, presented at theSociety for Neuroscience's 31st Annual Meeting, San Diego, CA (Nov. 12, 2001).
Domeniconi, M., et al., “Myelin-Associated Glycoprotein Interacts with the Nogo66 Receptor to Inhibit Neurite Outgrowth,”Neuron 35:283-290, Cell Press (Jul. 2002).
GrandPré , T., et al., “Nogo-66 receptor antagonist peptide promotes axonal regeneration,”Nature417:547-551, Nature Publishing Group (May 2002).
International Search Report for International Application No. PCT/US2005/002535, European Patent Office, Netherlands, mailed Oct. 24, 2005.
Li, M., et al., “Effect of soluble Nogo receptor treatment on functional and histological outcome after spinal cord injury in the rat,” Biosis Database, Accession No. PREV200400194121, Abstract No. 80.22,Presented at the 33rd Annual Meeting of the Society of Neuroscience, New Orleans, LA (Nov. 8-12, 2003).
Li, W., et al., “A Neutralizing Anti-Nogo66 Receptor Monoclonal Antibody Reverses Inhibition of Neurite Outgrowth by Central Nervous System Myelin,”J. Biol. Chem.42:43780-43788, The American Society for Biochemistry and Molecular Biology, Inc. (Oct. 2004).
Li, W., et al., “Neutralization of NGR1 May be Sufficient to Promote Rat DRG Neurite Outgrowth in the Presence of CNS Myeline,” SFN 2003 Abstract Viewer & Itinerary Planner, Program No. 678.3,Presented at the 33rd Annual Meeting of the Society of Neuroscience, New Orleans, LA (Nov. 8-12, 2003).
Oertle, T., et al., “Nogo-A Inhibits Neurite Outgrowth and Cell Spreading with Three Discrete Regions,”J. Neurosci.23:5393-5406, Society for Neuroscience (Jul. 2003).
O'Hara Eileen B.
Sterne Kessler Goldstein & Fox P.L.L.C.
Wegert Sandra
Yale University
LandOfFree
Nogo receptor-mediated blockade of axonal growth does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nogo receptor-mediated blockade of axonal growth, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nogo receptor-mediated blockade of axonal growth will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3670597